Zymeworks Inc. presented new Phase 1 data for ZW191, an antibody-drug conjugate targeting folate receptor alpha, showing promising anti-tumor activity in platinum-resistant ovarian cancer patients regardless of receptor expression levels. The confirmed objective response rate was 78.6% in FRα-positive and 47.4% in FRα-negative patients, with a median progression-free survival of 7.6 months. The drug demonstrated a manageable safety profile, supporting continued clinical development. Patient enrollment for dose optimization is complete, with further data expected to guide future dosing and development.
Crinetics Pharmaceuticals presented positive Phase 2 trial results for atumelnant, an oral ACTH receptor antagonist, showing it effectively lowers androgen levels and allows reduction of glucocorticoid doses in adults with classic congenital adrenal ...
Crypto markets faced pressure this week with Bitcoin stabilizing after a selloff and ETF outflows continuing. Despite this, AI and tech-related tokens like Audiera (BEAT) surged over 100%, driven by strong buying interest, while others like Bittensor...
MicroStrategy CEO Michael Saylor introduced new Bitcoin treasury metrics as the company's stock trades below its modified net asset value, reflecting concerns over its leveraged Bitcoin strategy. The new metrics, including CEBE BPS and Amplification,...
Charles Hoskinson, founder of Cardano, clarified that the 1,096 Bitcoin linked to Cardano's early ADA crowdsale were used to pay auditors who reviewed the fundraising process in 2016. The audit, requested by then-Cardano Foundation chairman Michael P...
The United States and Iran have reached a historic peace agreement, ending all military operations and easing tensions in the Middle East. This breakthrough, announced by Pakistani Prime Minister Shehbaz Sharif, is set to be formally signed on June 1...
